Miller PD, Bilezikian JP, Fitzpatrick LA, et al. Abaloparatide : an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Curr Med Res Opin 2020 ; 36 : 1861.
Hattersley G, Dean T, Corbin BA, et al. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology 2016 ; 157 : 141.
Doyle N, Varela A, Haile S, et al. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int 2018 ; 29 : 685.
Boyce RW, Paddock CL, Franks AF, et al. Effects of intermittent hPTH (1-34) alone and in combination with 1,25(OH) (2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 1996 ; 11 : 600.
Body JJ, Gaich GA, Scheele WIT, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002 ; 87 : 4528.